1. Ukita, Masayo, Hamanishi, Junzo, Yoshitomi, Hiroyuki, Ueno, Hideki, Mandai, Masaki. 2022. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. In JCI insight, 7, . doi:10.1172/jci.insight.157215. https://pubmed.ncbi.nlm.nih.gov/35552285/
2. Law, Calvin, Wacleche, Vanessa Sue, Cao, Ye, Choi, Jaehyuk, Rao, Deepak A. 2024. Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. In Nature, 631, 857-866. doi:10.1038/s41586-024-07627-2. https://pubmed.ncbi.nlm.nih.gov/38987586/
3. Hu, Xinyue, Ni, Songjia, Zhao, Kai, Qian, Jing, Duan, Yang. 2022. Bioinformatics-Led Discovery of Osteoarthritis Biomarkers and Inflammatory Infiltrates. In Frontiers in immunology, 13, 871008. doi:10.3389/fimmu.2022.871008. https://pubmed.ncbi.nlm.nih.gov/35734177/
4. Ma, Longfei, Yu, Lina, Jiang, Bao-Chun, Tao, Yuan-Xiang, Yan, Min. 2021. ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons. In The Journal of experimental medicine, 218, . doi:10.1084/jem.20210920. https://pubmed.ncbi.nlm.nih.gov/34762123/
5. Yang, Moran, Lu, Jiaqi, Zhang, Guodong, Xu, Congjian, Liu, Haiou. . CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. In Journal for immunotherapy of cancer, 9, . doi:10.1136/jitc-2020-001136. https://pubmed.ncbi.nlm.nih.gov/33452206/
智鼠故事 
